LOS ANGELES - The Los Angeles Biomedical Research Institute (LA BioMed) and BioLabs, a network of shared lab facilities designed to manage all aspects of operations for high-potential, early-stage life science companies, today announced the Spring 2019 opening of a new Los Angeles bioscience innovation center.
Funds will go toward recruiting top researchers and improving facilities in the South Bay region of LA County – one of the nation’s top ten biotech clusters
New Program Creates a Triple Threat: Graduates with Clinical, Business & Research Skills
LA BioMed has launched a doctoral program in translational research, the first comprehensive degree of its kind. It will be co-located with LA BioMed’s research facilities and biotech incubator in Torrance, alongside a future bioscience tech park, level one trauma center, and academic teaching hospital.
While male and female surgeons both work equally hard saving lives in the operating room, women in general surgery project earning significantly less than men. This disparity is due to women underestimating their future earning power, and to differing approaches to salary negotiation, according to an important new study from LA BioMed, an independent non-profit biomedical research organization.
Taking aim at one of the nation’s most common - but understudied - diseases, a team of local investigators have launched a groundbreaking study to determine the effectiveness of treatments for antibiotic-resistant skin infections.
The investigators from LA BioMed, one of the nation’s leading independent nonprofit research institutes, have been awarded a $5.3 million grant from the National Institutes of Health for their study, Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment.
Mucormycosis is a drug-resistant fungal infection that attacks patients with weakened immune systems and those who have suffered significant trauma. The infection can be easily missed by physicians because it is so rare and reliable diagnostic assay is lacking. Even when correctly diagnosed, it is often far too late and after the infection has spreads rapidly to vital organs, making most therapies ineffective. The mortality rate for those infected with mucormycosis is around 50%, according to the U.S. centers for Disease Control and Prevention.
LA BioMed President and Chief Executive Officer David Meyer, Ph.D., is set to elaborate on the future of the local bioscience industry during a panel discussion later today at the Los Angeles County 2018 Bioscience Summit. Meyer will also moderate a panel discussion about incubation and capital for start-ups.
LA BioMed, an independent biomedical research organization, hosted its fifth annual Innovation Showcase on September 13th in Manhattan Beach. The event featured some of biotechnology’s most promising start-ups and spotlighted 32 promising new bioscience companies.
LA BioMed invites media to their fifth annual Innovation Showcase on September 13th at westdrift in Manhattan Beach, CA. The Showcase will highlight some of biotechnology’s most promising start-ups and venture capital leaders.
Biotech start-up entrants from the growing incubation hub of LA will showcase innovation in next generation medical therapies, devices and diagnostics from some of the worlds’ leading scientists. Highlights from the 32 featured companies include: